{"entity":{"id":"paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020","kind":"paper","name":"REMORA: lenvatinib in advanced or metastatic thymic carcinoma","aka":[],"tldr":"In a Japanese trial the multi-kinase inhibitor lenvatinib shrank thymic carcinoma in about four in ten patients whose disease had progressed after platinum chemotherapy, leading to its approval in Japan.","summary":"Multicentre single-arm phase 2 trial of 42 patients with unresectable advanced or metastatic thymic carcinoma previously treated with platinum-based chemotherapy, given lenvatinib 24 mg daily.\n\nThe objective response rate was 38 percent and median progression-free survival 9.3 months. Hypertension and hand-foot syndrome were common and most patients needed dose reductions.","asOf":"2026-09-18","links":[{"label":"Lancet Oncol 2020","url":"https://doi.org/10.1016/S1470-2045(20)30162-5"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32502444/"}],"tags":[],"related":[],"cancers":["thymic-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["lenvatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30162-5","pmid":"32502444","authors":"Sato J, Satouchi M, Itoh S, et al.","paperType":"observational","findings":["Objective response rate 38 percent; median progression-free survival 9.3 months.","Grade 3 hypertension and palmar-plantar erythrodysaesthesia were frequent and dose reductions were the rule."],"whatItMeans":"Lenvatinib is one of the few drugs with prospective evidence in thymic carcinoma after chemotherapy, alongside sunitinib and pembrolizumab.","caveats":["Single-arm, single-country trial; no comparator.","Toxicity at the 24 mg dose limits use in frail patients."],"changedPractice":true,"participants":42},"route":"/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/","neighbours":{"cancer":[{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/"}],"drug":[{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}